Upstream Bio UPB
NASDAQ UPB
$3.20 -0.18 (-5.33%)
At close: Nov 11, 2026 · 4:00 PM EST

Upstream Bio (UPB) Return on Equity [ROE] (2024 - 2026)

Updated

Upstream Bio (UPB) recorded Return on Equity [ROE] of -54.44% in Q2 2026, down 30.00 percentage points from -24.44% a year earlier and down 5.76 percentage points from the prior quarter.

Analysis

Upstream Bio (UPB) Return on Equity [ROE] (2024 - 2026) Analysis & Trends

For FY2025, Upstream Bio reported Return on Equity [ROE] of -35.43%, up 2.43 percentage points from FY2024.

  • Across earlier years, Return on Equity [ROE] came in at -37.86% in FY2024.
  • Per Business Quant, the preceding three quarters came in at -48.69% (Q1 2026), -39.93% (Q4 2025) and -31.03% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 74.39%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 19.33%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 5.63%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 21.60%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 72.13%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -31.17%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 4.66%
10 Upstream Bio 185.26 Mn -919.50 Mn - -65.26%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -65.26%
Jun 30, 2026 -54.57%
Mar 31, 2026 -48.79%
Dec 31, 2025 -39.78%
Sep 30, 2025 -31.01%
Jun 30, 2025 -24.38%
Mar 31, 2025 -17.21%
Dec 31, 2024 -40.61%
API Access

Upstream Bio Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=UPB&period=max&api_key=YOUR_API_KEY